Childhood Cancer Research Unit, Department of Women's and Children's Health.
Astrid Lindgren Children's Hospital, Karolinska University Hospital.
J Pediatr Hematol Oncol. 2021 Mar 1;43(2):e272-e275. doi: 10.1097/MPH.0000000000001808.
Extracorporeal membrane oxygenation (ECMO) is used in severe respiratory and/or circulatory failure when conventional critical care fails. Studies on patients with hematologic malignancies on ECMO have shown contradictory results; immunosuppression and coagulopathy are relative contraindications to ECMO.
This nationwide Swedish retrospective chart review identified 958 children with hematologic malignancies of whom 12 (1.3%) required ECMO support. Eight patients survived ECMO, 7 the total intensive care period, and 6 survived the underlying malignancy.
ECMO may be considered in children with hematologic malignancy. Short-term and long-term survival, in this limited group, was similar to that of children on ECMO at large.
体外膜肺氧合（ECMO）用于常规重症监护失败时严重呼吸和/或循环衰竭的患者。在接受 ECMO 的血液系统恶性肿瘤患者的研究中，结果存在矛盾；免疫抑制和凝血障碍是 ECMO 的相对禁忌证。
这项全国性的瑞典回顾性图表研究纳入了 958 名血液系统恶性肿瘤患儿，其中 12 名（1.3%）需要 ECMO 支持。8 名患者在 ECMO 治疗中存活，7 名患者在整个重症监护期间存活，6 名患者在恶性肿瘤中存活。
在血液系统恶性肿瘤患儿中可以考虑使用 ECMO。该有限组的短期和长期生存率与总体 ECMO 患儿相似。
